Journal List > J Rheum Dis > v.21(6) > 1064155

Lee and Choe: Development of Crohn's Disease during Etanercept Treatment in Juvenile Idiopathic Arthritis

REFERENCES

1. Dallocchio A, Canioni D, Ruemmele F, Duquesne A, Scoazec JY, Bouvier R, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford). 2010; 49:1694–8.
crossref
2. Wiegering V, Morbach H, Dick A, Girschick HJ. Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int. 2010; 30:801–4.
crossref
3. Toussirot É, Houvenagel É, Goëb V, Fouache D, Martin A, Le Dantec P, et al. Le CRI. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine. 2012; 79:457–63.
crossref
4. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001; 121:1088–94.
crossref
5. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003; 124:1774–85.
crossref

Figure 1.
Dynamic CT scan shows irregular mural thickening and enhancement in IC valve and terminal ileum in initial study (A), and much improved inflammation in follow-up study (B).
jrd-21-340f1.tif
Figure 2.
Endoscopic finding shows multiple various sized shallow ulcers with inflammatory polyposis at terminal ileum.
jrd-21-340f2.tif
Figure 3.
Light microscopy shows chronic inflammation with noncaseous granuloma.
jrd-21-340f3.tif
TOOLS
Similar articles